Achillion prices shares to net $118.5m for HCV drug combo development
This article was originally published in Scrip
Executive Summary
Achillion Pharmaceuticals priced 15 million shares of common stock at $8.40 per share for net proceeds of $118.5 million to advance its lead hepatitis C virus (HCV) drug candidates – sovaprevir, ACH-3102 and ACH-2684 – into late-stage development.